Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| TECH | BIO-TECHNE Corp | 2025-10-28 16:07:49 | 64.4 | 0.46 | 0.72 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TECH | 0000842023 | BIO-TECHNE Corp | US09073M1045 | 54930073RLKQ51TILZ35 | 411427402 | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 0630 | MN | 614 MCKINLEY PL N E | MINNEAPOLIS | MN | 55413 | UNITED STATES | US | 612-379-8854 | 614 MCKINLEY PLACE NE, MINNEAPOLIS, MN, 55413 | 614 MCKINLEY PL N E, MINNEAPOLIS, MN, 55413 | TECHNE CORP /MN/ | Biotechnology | 1976 | Kim Kelderman | 3,100 | http://bio-techne.com | 11,400,000,000 | 154,972,196 | 155,549,587 | Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets. | 2025-10-23 13:00:39 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 11,400,000,000 | -700,000,000 | -5.7851 | 155,549,587 | -3,050,821 | -1.9236 |
| 2024 | 12,100,000,000 | -900,000,000 | -6.9231 | 158,600,408 | 426,096 | 0.2694 |
| 2023 | 13,000,000,000 | -7,300,000,000 | -35.9606 | 158,174,312 | 118,962,279 | 303.3821 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Matthew Mcmanus | President | 2025 | 572,000 | 0 | 1,213,200 | 444,787 | 19,937 | 2,846,619 |
| Kim Kelderman | President, CEO | 2025 | 936,000 | 0 | 3,929,942 | 1,318,917 | 33,473 | 8,151,181 |
| James Hippel | CFO, Executive Vice President | 2025 | 723,000 | 0 | 4,453,020 | 926,163 | 17,926 | 7,027,382 |
| William Geist | President | 2025 | 573,200 | 0 | 1,206,585 | 748,026 | 18,040 | 3,139,299 |
| Shane Bohnen | General Counsel, Senior Vice President | 2025 | 431,000 | 0 | 767,575 | 386,478 | 18,183 | 1,980,732 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 3,100 |
| 2024 | 3,100 |
| 2023 | 3,050 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 1,219,635,000 | 1,159,060,000 | 1,136,702,000 |
| Cost Of Revenue | 429,363,000 | 389,335,000 | 366,887,000 |
| Gross Profit | 790,272,000 | 769,725,000 | 769,815,000 |
| Research And Development Expenses | 99,496,000 | 96,664,000 | 92,493,000 |
| General And Administrative Expenses | 588,521,000 | 466,375,000 | 378,378,000 |
| Operating Expenses | 688,017,000 | 563,039,000 | 470,871,000 |
| Operating Income | 102,255,000 | 206,686,000 | 298,944,000 |
| Net Income | 73,400,000 | 168,105,000 | 285,263,000 |
| Earnings Per Share Basic | 0.47 | 1.07 | 1.81 |
| Earnings Per Share Diluted | 0.46 | 1.05 | 1.76 |
| Weighted Average Shares Outstanding Basic | 157,521,000 | 157,708,000 | 157,179,000 |
| Weighted Average Shares Outstanding Diluted | 159,717,000 | 160,774,000 | 161,855,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 162,186,000 | 151,791,000 | 180,571,000 |
| Marketable Securities Current | — | 1,072,000 | 23,739,000 |
| Accounts Receivable | 206,876,000 | 241,394,000 | 218,468,000 |
| Inventories | 189,446,000 | 179,731,000 | 171,638,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 37,460,000 | 33,658,000 | 27,066,000 |
| Total Assets Current | 608,300,000 | 617,419,000 | 621,482,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 245,719,000 | 251,154,000 | 226,200,000 |
| Other Assets Non Current | 273,609,000 | 264,265,000 | 285,302,000 |
| Total Assets Non Current | 245,719,000 | 251,154,000 | 226,200,000 |
| Total Assets | 2,557,868,000 | 2,703,867,000 | 2,638,692,000 |
| Accounts Payable | 25,311,000 | 37,968,000 | 25,679,000 |
| Deferred Revenue | 32,571,000 | 27,930,000 | 23,069,000 |
| Short Term Debt | 346,000,000 | 319,000,000 | 350,000,000 |
| Other Liabilities Current | 1,645,000 | 2,151,000 | 1,413,000 |
| Total Liabilities Current | 175,849,000 | 159,379,000 | 128,509,000 |
| Long Term Debt | 346,000,000 | 319,000,000 | 350,000,000 |
| Other Liabilities Non Current | 27,082,000 | 13,157,000 | 10,919,000 |
| Total Liabilities Non Current | — | — | — |
| Total Liabilities | — | — | — |
| Common Stock | 1,550,000 | 1,582,000 | 1,576,000 |
| Retained Earnings | 1,066,049,000 | 1,325,247,000 | 1,309,461,000 |
| Accumulated Other Comprehensive Income | -59,880,000 | -78,316,000 | -66,064,000 |
| Total Shareholders Equity | 1,918,808,000 | 2,068,850,000 | 1,966,516,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 109,903,000 | 111,711,000 | 107,238,000 |
| Share Based Compensation Expense | 40,833,000 | 38,042,000 | 39,230,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | -34,132,000 | 20,533,000 | 20,867,000 |
| Change In Inventories | 18,144,000 | 14,215,000 | 30,167,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -13,954,000 | 25,769,000 | -7,908,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 287,556,000 | 298,981,000 | 254,393,000 |
| Purchases Of Marketable Securities | — | 5,526,000 | 20,500,000 |
| Sales Of Marketable Securities | 1,085,000 | 28,083,000 | 35,236,000 |
| Acquisition Of Property Plant And Equipment | 31,006,000 | 62,877,000 | 38,244,000 |
| Acquisition Of Business | — | 169,707,000 | 101,184,000 |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -35,183,000 | -203,030,000 | -265,649,000 |
| Tax Withholding For Share Based Compensation | 6,522,000 | 21,872,000 | 28,893,000 |
| Payments Of Dividends | 50,391,000 | 50,419,000 | 50,285,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 275,731,000 | 80,042,000 | 19,562,000 |
| Issuance Of Long Term Debt | 104,000,000 | 225,000,000 | 619,661,000 |
| Repayment Of Long Term Debt | 77,000,000 | 256,000,000 | 525,661,000 |
| Other Financing Activities | — | — | -2,457,000 |
| Cash From Financing Activities | -253,905,000 | -122,398,000 | 22,616,000 |
| Change In Cash | 10,395,000 | -28,780,000 | 8,004,000 |
| Cash At End Of Period | 162,186,000 | 151,791,000 | 180,571,000 |
| Income Taxes Paid | 74,357,000 | 65,254,000 | 88,428,000 |
| Interest Paid | 18,955,000 | 14,502,000 | 8,368,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 0.47 | 1.07 | 1.81 |
| Price To Earnings Ratio | 109.4681 | 66.9252 | 45.0994 |
| Earnings Growth Rate | -56.0748 | -40.884 | -73.8817 |
| Price Earnings To Growth Ratio | -1.9522 | -1.637 | -0.6104 |
| Book Value Per Share | 15.1219 | 16.1342 | 15.9702 |
| Price To Book Ratio | 3.4023 | 4.4384 | 5.1114 |
| Ebitda | 266,169,000 | 360,806,000 | 492,144,000 |
| Enterprise Value | 8,634,269,450 | 11,779,678,880 | 13,349,950,770 |
| Dividend Yield | 0.0062 | 0.0045 | 0.0039 |
| Dividend Payout Ratio | 0.6865 | 0.2999 | 0.1763 |
| Debt To Equity Ratio | 0.3606 | 0.3084 | 0.356 |
| Capital Expenditures | 104,468,000 | 136,665,000 | 110,196,000 |
| Free Cash Flow | 183,088,000 | 162,316,000 | 144,197,000 |
| Return On Equity | 0.0383 | 0.0813 | 0.1451 |
| One Year Beta | 1.1714 | 1.0614 | 1.136 |
| Three Year Beta | 1.1387 | 1.1445 | 1.1576 |
| Five Year Beta | 1.1512 | 0.9214 | 0.9403 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| BAUMGARTNER ROBERT V | Director | 2025-08-25 | 17,040 | A | 61,903 |
| BAUMGARTNER ROBERT V | Director | 2025-08-25 | 17,040 | D | 44,863 |
| BAUMGARTNER ROBERT V | Director | 2025-08-25 | 17,040 | D | 0 |
| Nusse Roeland | Director | 2025-08-25 | 17,040 | A | 61,599 |
| Nusse Roeland | Director | 2025-08-25 | 17,040 | D | 44,559 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Thomas R Tillis | Senator | 2015-02-26 | Sale (Full) | 2015-02-13 | Joint | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| April McClain Delaney | 2025-09-02 | MD06 | Sale (Partial) | 2025-08-01 | Child | $1,001 - $15,000 |
| April McClain Delaney | 2025-07-02 | MD06 | Sale (Partial) | 2025-05-26 | Child | $1,001 - $15,000 |
| Julie Johnson | 2025-05-14 | TX32 | Sale | 2025-04-01 | Joint | $1,001 - $15,000 |
| Rob Bresnahan | 2025-05-08 | PA08 | Sale | 2025-04-08 | — | $1,001 - $15,000 |
| April McClain Delaney | 2025-05-02 | MD06 | Purchase | 2025-04-09 | Child | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| QRG CAPITAL MANAGEMENT, INC. | 2025-09-30 | 618,501 | 11,118 | 55.6306 |
| LEAVELL INVESTMENT MANAGEMENT, INC. | 2025-09-30 | 2,276,825 | 40,928 | 55.63 |
| Stephens Investment Management Group LLC | 2025-09-30 | 56,474,964 | 1,015,189 | 55.63 |
| Pembroke Management, LTD | 2025-09-30 | 20,971,231 | 376,977 | 55.63 |
| ASR Vermogensbeheer N.V. | 2025-09-30 | 139,687 | 2,511 | 55.63 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| FORUM FUNDS | 2025-09-30 | Institutional Plus Shares | DFMLX | 231,959 | 12,903,879.17 | 3.5256 |
| FORUM FUNDS | 2025-09-30 | Institutional Plus Shares | DFSLX | 84,169 | 4,682,321.47 | 2.6087 |
| FORUM FUNDS | 2025-09-30 | Institutional Shares | DFSGX | 84,169 | 4,682,321.47 | 2.6087 |
| FORUM FUNDS | 2025-09-30 | Institutional Shares | DFMGX | 231,959 | 12,903,879.17 | 3.5256 |
| FORUM FUNDS | 2025-09-30 | Investor Shares | DFDMX | 231,959 | 12,903,879.17 | 3.5256 |